Skip Nav Destination
1-2 of 2
Bijal D. Shah, MD, Wendy Stock, MD, William G Wierda, MD PhD, Olalekan Oluwole, MBBS, MPH, Houston Holmes, MD FACP, Gary J. Schiller, MD FACP, Max S. Topp, MD, Marie José Kersten, MD PhD, Roch Houot, MD PhD, Nicolas Boissel, MD PhD, Michelle Mojadidi, MSc, Allen Xue, PhD, Armen Mardiros, PhD, Yizhou Jiang, PhD, Tong Shen, PhD, Jeff S. Aycock, Shanna Stout, Jeffrey S. Wiezorek, MD MS, Rajul Jain, MD
Blood (2017) 130 (Suppl_1): 888.
High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials
Bijal Shah, MD, Van Huynh, MD, Leonard S. Sender, MD, Daniel W. Lee, III, MD, Januario E. Castro, MD, William G. Wierda, MD PhD, Andrew C. Dietz, MD MSCR, Gary J. Schiller, MD, Marie José Kersten, MD PhD, Rupert Handgretinger, MD PhD, Patrick Brown, MD, Lia Gore, MD, Nicola Gökbuget, MD, Joseph Rosenthal, MD MS, Marianna Sabatino, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Yizhou Jiang, PhD, Lynn Navale, MS, Shanna Stout, BS, Jeff S. Aycock, BA, Jeff Wiezorek, MD MS, Rajul Jain, MD, Alan S. Wayne, MD
Blood (2016) 128 (22): 2803.